- Home
- MCRB vs ANTX Comparison
MCRB vs ANTX Comparison
Compare MCRB & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | ANTX |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 135.4M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MCRB | ANTX |
|---|---|---|
| Price | $9.42 | $5.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.33 | $2.00 |
| AVG Volume (30 Days) | 46.0K | ★ 3.2M |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $789,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.00 |
| 52 Week High | $29.98 | $6.91 |
Technical Indicators
Market Signals| Indicator | MCRB | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 77.80 |
| Support Level | $6.99 | $1.05 |
| Resistance Level | $9.60 | $6.91 |
| Average True Range (ATR) | 0.53 | 0.78 |
| MACD | 0.24 | 0.31 |
| Stochastic Oscillator | 77.57 | 67.07 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.